Intralesional injections of T-VEC heightens the immune response by increasing infiltrating CD8+ T cells and IFN-γ gene and PD-L1 protein expression within the tumor microenvironment, thus turning an immune-desolate tumor into an immunogenic tumor, making the tumor more susceptible to ICI treatment. Here, CD8A is linked to neoplasm.